Table 1.
Patient characteristics
| BCR patients’ characteristics | N |
Mets N (group %) |
No-Mets N (group %) |
Pearson’s Chi-squared, Fisher exact or Wilcoxon-rank significance test (P) |
|---|---|---|---|---|
| Study cohort | 85 | 51 | 34 | |
| Age | 0.822 | |||
| 46–60 | 35 | 21 (41) | 14 (41) | |
| 61–74 | 50 | 30 (59) | 20 (59) | |
| Pre-operative PSA | 0.40 | |||
| <10 ng ml−1 | 38 | 22 (43) | 16 (47) | |
| 10–20 ng ml−1 | 28 | 15 (29) | 13 (38) | |
| >20 ng ml−1 | 19 | 14 (28) | 5 (15) | |
| Pathological Gleason Score | 0.0029 | |||
| ≤6 | 4 | 0 (0.0) | 4 (12) | |
| 7 | 44 | 23 (86) | 21 (62) | |
| ≥8 | 37 | 28 (55) | 9 (26) | |
| Seminal vesicle invasion | 38 | 29 (57) | 9 (27) | 0.011 |
| Positive surgical margin | 50 | 29 (57) | 21 (62) | 0.822 |
| Extra-capsular extension | 50 | 36 (71) | 14 (41) | 0.013 |
| Lymph node involvement | 17 | 13 (25) | 4 (12) | 0.168 |
| Prostate cancer-specific mortality | 22 | 22 (43) | 0 (0) | — |
| Adjuvant radiation therapy | 11 | 8 (16) | 3 (8) | 0.552 |
| Adjuvant androgen deprivation therapy | 37 | 29 (57) | 8 (24) | 0.005 |
| Salvage radiation therapy | 36 | 22 (43) | 14 (41) | 0.182 |
| Salvage androgen deprivation therapy | 43 | 30 (59) | 13 (38) | 0.009 |
| Time to BCR | 0.19 | |||
| ≤2 years | 51 | 34 (67) | 17 (50) | |
| >2 years | 34 | 17 (33) | 17 (50) | |
| PSAdT (NA = 12) | 0.006 | |||
| ≤9 months | 48 | 33 (65) | 15 (44) | |
| >9 months | 25 | 8 (16) | 17 (50) |
Abbreviations: BCR, biochemical recurrence; Mets, metastasis following BCR; PSAdT, PSA doubling time.